136 related articles for article (PubMed ID: 36733054)
41. Successfully-treated mesenteric non-Hodgkin's lymphoma involving hepatic mass--a case report.
Yamaguchi T; Takahashi H; Kagawa R; Takeda R; Sakata S; Yamamoto M; Nishizaki D; Takamatsu T; Iwasa Y
Gan To Kagaku Ryoho; 2007 May; 34(5):783-7. PubMed ID: 17496458
[TBL] [Abstract][Full Text] [Related]
42. Primary diffuse large B cell lymphoma (DLBCL) of the prostate presenting with lower urinary tract symptoms (LUTS).
Nusrat A; Nazim SM
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370963
[TBL] [Abstract][Full Text] [Related]
43. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
[TBL] [Abstract][Full Text] [Related]
44. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
Shimazu Y; Nohgawa M
J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
[No Abstract] [Full Text] [Related]
45. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
46. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
[TBL] [Abstract][Full Text] [Related]
47. [Recent development of hypertension and acute renal failure in a 59-year-old woman].
Uebner M; Jacobi J; Schmidt D; Büttner-Herold M; Mackensen A; Spriewald BM
Internist (Berl); 2017 Dec; 58(12):1319-1323. PubMed ID: 28555379
[TBL] [Abstract][Full Text] [Related]
48. Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone.
Nasu K; Okamoto M; Nishida M; Takai N; Narahara H
Eur J Gynaecol Oncol; 2012; 33(2):219-22. PubMed ID: 22611969
[TBL] [Abstract][Full Text] [Related]
49. Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.
Maggen C; Dierickx D; Cardonick E; Mhallem Gziri M; Cabrera-Garcia A; Shmakov RG; Avivi I; Masturzo B; Duvekot JJ; Ottevanger PB; O'Laughlin A; Polushkina E; Van Calsteren K; Woei-A-Jin FJSH; Amant F;
Br J Haematol; 2021 Apr; 193(1):52-62. PubMed ID: 32945547
[TBL] [Abstract][Full Text] [Related]
50. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
[TBL] [Abstract][Full Text] [Related]
51. [A Case of Diffuse Large B-Cell Lymphoma of the Ascending Colon].
Hashimoto I; Abe Y; Nagasawa S; Tamagawa H; Rino Y; Masuda M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2264-2266. PubMed ID: 32156899
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
53. A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors.
Yamada R; Sakuno T; Inoue H; Miura H; Takeuchi T; Shiono Y; Okuse H; Nakamura M; Katsurahara M; Hamada Y; Tanaka K; Horiki N; Takei Y
Clin J Gastroenterol; 2018 Aug; 11(4):286-290. PubMed ID: 29546569
[TBL] [Abstract][Full Text] [Related]
54. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
[TBL] [Abstract][Full Text] [Related]
55. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
56. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
Chen-Liang TH; Martín-Santos T; Jerez A; Rodríguez-García G; Senent L; Martínez-Millán C; Muiña B; Orero M; Teruel A; Martín A; Gómez-Espuch J; Kennedy K; Benet C; Raya JM; Fernández-González M; de la Cruz F; Guinot M; Villegas C; Ballester I; Baile M; Moya M; López-Jiménez J; Frutos L; Navarro JL; Uña J; Fernández-López R; Igua C; Contreras J; Sánchez-Vañó R; Cozar MDP; Tamayo P; Mucientes J; Sánchez-Blanco JJ; Pérez-Ceballos E; Ortuño FJ
Cancer Med; 2017 Nov; 6(11):2507-2514. PubMed ID: 28960797
[TBL] [Abstract][Full Text] [Related]
57. Peritoneal lymphomatosis: CT findings.
Kim Y; Cho O; Song S; Lee H; Rhim H; Koh B
Abdom Imaging; 1998; 23(1):87-90. PubMed ID: 9437071
[TBL] [Abstract][Full Text] [Related]
58. Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Cho H; Yoon DH; Kim JH; Ko YB; Kwon BS; Song IH; Suh C
Korean J Intern Med; 2016 May; 31(3):605-7. PubMed ID: 26968186
[No Abstract] [Full Text] [Related]
59. Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse-a case report.
Suresh Babu MC; Thottian AGF; Lokanatha D; Jacob LA; Lokesh KN; Rudresha AH; Rajeev LK; Smitha S; Hassan SA; Ashok KP; Premalatha CS; Suma MN
J Egypt Natl Canc Inst; 2020 May; 32(1):22. PubMed ID: 32410046
[TBL] [Abstract][Full Text] [Related]
60. Isolated peritoneal lymphomatosis defined as post-transplant lymphoproliferative disorder after a liver transplant: A case report.
Kim HB; Hong R; Na YS; Choi WY; Park SG; Lee HJ
World J Clin Cases; 2019 Dec; 7(24):4299-4306. PubMed ID: 31911911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
